Search clinical trials for: 4-aminopyridine

Total 4078 results

Acorda Therapeutics

Completed

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada
National Center for Research Resources (NCRR)
Mayo Clinic

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Jeffrey A. Cohen, MD
Jacobus Pharmaceutical

Terminated

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) (3-4DAP)

Muscle Weakness

United States
Coordinación de Investigación en Salud, Mexico

Completed

Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis

Multiple Sclerosis

Mexico
FDA Office of Orphan Products Development

Completed

Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine

Guillain-Barre Syndrome

United States
University of Rochester

Withdrawn

4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy

Prostate Disease

United States
Acorda Therapeutics

Completed

Study of Oral Fampridine-SR in Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Completed

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Multiple Sclerosis

United States, Canada
Columbia University

Completed

Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients

Spinal Muscular Atrophy

United States
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Kessler Foundation
National Institute on Disability, Independent Living, and Rehabilitation... and other collaborators

Completed

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury

Spinal Cord Injury

United States
University of Zurich

Unknown

Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis (FAMPKIN)

Multiple Sclerosis

Switzerland
John Elfar
University of Arizona

Active, not recruiting

4-aminopyridine Treatment for Nerve Injury

Prostate Cancer | Nerve Injury

United States
Coordinación de Investigación en Salud, Mexico

Active, not recruiting

High Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients.

Spinal Cord Injuries | Chronic

Mexico
John Elfar

Not yet recruiting

4AP to Delay Carpal Tunnel Release (CTR) (CTR)

Carpal Tunnel Syndrome | Compression Neuropathy
University of Southern Denmark
Odense University Hospital; Fonden til Lægevidenskabens Fremme; Sygehus Lillebaelt and other collaborators

Completed

Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique (MUST)

Multiple Sclerosis

Denmark
Genesis Pharma CNS & Specialty

Completed

Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis (FAMILY)

Multiple Sclerosis

Greece
Brigham and Women's Hospital

Completed

Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults (APIGLOSS)

Sleep Apnea, Obstructive

United States
University of California, Los Angeles
University of South Florida; University of Rochester

Withdrawn

4-Aminopyridine in Episodic Ataxia Type 2 (4AP in EA2)

Episodic Ataxia Type 2

United States
University of Arizona
National Institute of Neurological Disorders and Stroke (NINDS)

Not yet recruiting

4-AP Peripheral Nerve Crossover Trial

Peripheral Nerve Injury | Crush Injury
Hospital for Special Surgery, New York

Active, not recruiting

Use of Dalfampridine in Primary Lateral Sclerosis

Motor Neuron Disease, Upper

United States
John Elfar

Not yet recruiting

4-aminopyridine for Skin Wound Healing

Wounds and Injuries | Wound Heal | Wounds | Wound of Skin

United States
Prof. Dominique de Quervain, MD
University Hospital, Basel, Switzerland; Clinical Trial Unit, University Hospital...

Recruiting

Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment (FamC)

Working Memory | Post-covid-19

Switzerland
Prof. Dominique de Quervain, MD
University Hospital, Basel, Switzerland; Clinical Trial Unit, University Hospital...

Withdrawn

Influence of Fampridine on Working Memory in Healthy Subjects (Fampyr_2020)

Working Memory

Switzerland
State University of New York at Buffalo

Completed

Effects of Dalfampridine on Cognition in Multiple Sclerosis

Multiple Sclerosis

United States
VA Office of Research and Development

Completed

Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

Multiple Sclerosis | Fatigue | Internuclear Ophthalmoplegia

United States
Acorda Therapeutics

Completed

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

Muscle Spasticity | Spinal Cord Injury

United States, Canada
Courtney Casserly

Recruiting

Fampridine-SR and Optic Neuritis Recovery (FAMP-ON)

Optic Neuritis

Canada
Prof. Dominique de Quervain, MD
University Hospital, Basel, Switzerland; Clinical Trial Unit, University Hospital...

Completed

Influence of Fampridine on Working Memory in Healthy Young Subjects (FamH)

Working Memory

Switzerland
University College Dublin

Completed

A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

Ireland
Oregon Health and Science University
Acorda Therapeutics

Completed

Dalfampridine for Imbalance in Multiple Sclerosis

Multiple Sclerosis | Fatigue

United States
Acorda Therapeutics

Completed

Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment

Renal Insufficiency

United States
London Health Sciences Centre

Completed

Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?

Cognitive Fatigue

Canada
Acorda Therapeutics

Completed

Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

Cerebral Palsy (CP)

United States
Massachusetts Eye and Ear Infirmary

Withdrawn

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

Migraine Disorders | Vestibular Diseases | Vestibular Migraine

United States
Acorda Therapeutics

Completed

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

Muscle Spasticity | Spinal Cord Injury

United States, Canada
Centre Hospitalier Universitaire de Besancon

Completed

Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. (FAMPISEP)

Multiple Sclerosis

France
University of Southern Denmark
Biogen; Region of Southern Denmark

Completed

Resistance Training and Amino Pyridine in Multiple Sclerosis (RETRAP)

Multiple Sclerosis

Denmark
Neuro-Ophthalmologic Associates, PC
Acorda Therapeutics

Completed

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (Ampyra)

Non Arteritic Ischemic Optic Neuropathy

United States
Shirley Ryan AbilityLab
National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

Effects of 4-AP on Functional SCI Recovery

Spinal Cord Injury

United States
D'Youville College
University at Buffalo; Acorda Therapeutics

Completed

Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis

Multiple Sclerosis
University of Florida
Acorda Therapeutics

Completed

Dalfampridine and Gait in Spinocerebellar Ataxias

Spinocerebellar Ataxias Type 1 | Spinocerebellar Ataxias Type 2 | Spinocerebellar Ataxias Type 3 | Spinocerebellar Ataxias Type 6

United States
Clinique Neuro-Outaouais
CogState Ltd.

Completed

Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients

Multiple Sclerosis

Canada
European University of Lefke

Completed

Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia

Hereditary Spastic Paraplegia

Cyprus
Johns Hopkins University
Acorda Therapeutics

Completed

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Neuromyelitis Optica | Transverse Myelitis | Idiopathic Transverse Myelitis | Myelitis NOS

United States
Acorda Therapeutics

Completed

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

Ischemic Stroke

United States
Acorda Therapeutics
Prometrika, LLC; BCS Consulting, Inc.

Completed

An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Milton S. Hershey Medical Center

Terminated

A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma

Nerve Injury

United States

Search clinical trials for: 4-aminopyridine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations